The Phase 2 paper reported an estimated mean weight change of −8.7% at 48 weeks in the 1 mg retatrutide group, compared with −2.1% in the shared placebo group.
The lowest Phase 2 target group
The comparison describes an assigned group and a specific trial population. It does not determine what would happen with self-directed use or a different formulation.
How to interpret the evidence
Trace the number to the weight-results table and read the trial eligibility and safety sections alongside it.
This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.